Soleno Therapeutics, Inc. (SLNO) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$52.95
Price Target
$80.00
Target Range
$53.00 — $107.00
Analyst Rating
Buy
Forward P/E13.4x
Trailing P/E135.8x
Forward PEG—
Implied Growth+926.9%
Median Target$80.00
Analyst Spread67.5%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$53
+0.1%
Consensus
$80
+51.1%
Bull Case
$107
+102.1%
SLNO Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Soleno Therapeutics, Inc. (SLNO) has a Wall Street consensus price target of $80.00, based on estimates from 13 covering analysts. With the stock currently trading at $52.95, this represents a potential upside of +51.1%. The company has a market capitalization of $2.76B.
Analyst price targets range from a low of $53.00 to a high of $107.00, representing a 68% spread in expectations. The median target of $80.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, SLNO trades at a trailing P/E of 135.8x and forward P/E of 13.4x. Analysts expect EPS to grow +926.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+38.5%
Avg Forward P/E38.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 RYTMRhythm Pharmaceuticals, Inc. | $6.6B | $96.23 | $140.00 | +45.5% | Buy | — | 20 |
 MDGLMadrigal Pharmaceuticals, Inc. | $12.3B | $534.86 | $705.67 | +31.9% | Buy | — | 23 |
 PTCTPTC Therapeutics, Inc. | $5.3B | $64.49 | $89.67 | +39.0% | Buy | — | 26 |
 ANABAnaptysBio, Inc. | $2.9B | $66.96 | $73.88 | +10.3% | Buy | — | 22 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $8.7B | $296.70 | $332.75 | +12.2% | Buy | 39.3x | 17 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 LGNDLigand Pharmaceuticals Incorporated | $4.1B | $210.33 | $267.75 | +27.3% | Buy | 23.6x | 17 |
Upside Potential Comparison
RAREIMVTACADRYTMPTCTMDGLLGNDKRYSSee SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLNO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is the SLNO stock price target for 2026?
The consensus Wall Street price target for SLNO is $80, representing 51.1% upside from the current price of $52.95. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is SLNO a buy, sell, or hold?
SLNO has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $80 implies 51.1% upside from current levels.
Is SLNO stock overvalued or undervalued?
With a forward P/E of 13.4108x, SLNO trades at a relatively low valuation. The consensus target of $80 implies 51.1% appreciation, suggesting meaningful undervaluation.
How high can SLNO stock go?
The most bullish Wall Street analyst has a price target of $107 for SLNO, while the most conservative target is $53. The consensus of $80 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SLNO stock?
SLNO is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SLNO stock forecast?
The 12-month SLNO stock forecast based on 13 Wall Street analysts shows a consensus price target of $80, with estimates ranging from $53 (bear case) to $107 (bull case). The median consensus rating is "Buy".
What is SLNO's forward P/E ratio?
SLNO trades at a forward P/E ratio of 13.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 135.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy SLNO stock?
Wall Street analysts are very optimistic on SLNO, with a "Buy" consensus rating and $80 price target (51.1% upside). 8 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SLNO price targets vary so much?
SLNO analyst price targets range from $53 to $107, a 68% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $80 consensus represents the middle ground.